1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
NIGMS Technology Development Programs (R21 and R01) is sponsored by National Institute of General Medical Sciences (NIGMS) within NIH. NIGMS supports technology development that aligns with its mission of understanding biological processes and laying the foundation for advances in disease diagnosis, treatment, and prevention, particularly in areas not responsive to disease-specific or organ-specific NIH Institu…
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
NIGMS Technology Development Programs (R21 and R01) | National Institute of General Medical Sciences NIGMS Technology Development Programs (R21 and R01): The advance biomedical research.
Example technologies, which might originate from biomedical, engineering, or physical sciences disciplines, include instruments, devices, processes, algorithms, software, chemicals, biomolecules, or cells that have potential value for generating new basic biomedical research.
The NOFOs support the earliest stages of technology development, establishing feasibility/proof of concept, and prototype validation, and do not support applications that address new biological questions. Investigators are strongly encouraged to contact program staff ( NIGMS_TechDev@nigms. nih.
gov ) prior to and in preparation for submitting an application to these programs.
Proof of Concept and Value Exploratory Research / Technology Feasibility Technology Development R21 Iterative Technology R&D / Validation Studies Technology Development R01 Addressing Biological Questions Applied technology R&D and Dissemination Testing Biological Questions Late-Stage Technology Optimization for Broad Utility and Self-Sustaining Dissemination Biomedical Technology Optimization & Dissemination RM1 Frequently Asked Questions Send your questions about the programs to the NIGMS tech dev contact mailbox .
Technology Commercialization through Small Business Concept to Clinic: Commercializing Innovation Program This page last updated on
According to the current listing, eligibility includes: Academic institutions and researchers. R21 requires novel, high-risk approaches with unpublished data not allowed. R01 allows preliminary data to support feasibility. Confirm the full requirements in the official notice before applying.
The current listing shows up to $275,000 for R21; unlimited for R01 (within actual project needs). Verify award ceilings, matching requirements, and allowable costs in the official notice.
NIGMS Technology Development Programs (R21 and R01) is funded by National Institute of General Medical Sciences (NIGMS) within NIH. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
PAR-27-056 replaces the long-running IDeA-CTR U54 cooperative agreement with a P30 center core grant and splits the program into Development and Network tracks. Posted August 19, 2026, with a first estimated due date of October 9. Here is what the mechanism swap actually changes for the 23 IDeA states and Puerto Rico.
Read articleThe memorandum of agreement was signed August 4 and 5, disclosed by House appropriators on September 3, and runs through 2036. It names no dollar figure. Here is what is actually established, what is still speculation, and what researchers holding or planning NIAID biodefense awards should do before September 30.
Read articlePAR-27-054 and PAR-27-055 replace COBRE's Phase 1-2-3 model with two tracks: a 15-year Development-Expansion-Sustainability path and a 10-year Expansion-Sustainability path. At $1.5 million per year in direct costs across 23 states and Puerto Rico, with new research cores prohibited in the final phase and eligibility capped at three active awards per institution, the track you claim is the most consequential choice in the application.
Read article